The discovery that CE potentiated the anticancer activity of AF is somewhat surprising, since CE is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclo-oxygenase-2 (COX-2). This evidence concerns the gene PTGS2 and atrial fibrillation.